302 related articles for article (PubMed ID: 29047224)
1. Ral signaling pathway in health and cancer.
Moghadam AR; Patrad E; Tafsiri E; Peng W; Fangman B; Pluard TJ; Accurso A; Salacz M; Shah K; Ricke B; Bi D; Kimura K; Graves L; Najad MK; Dolatkhah R; Sanaat Z; Yazdi M; Tavakolinia N; Mazani M; Amani M; Ghavami S; Gartell R; Reilly C; Naima Z; Esfandyari T; Farassati F
Cancer Med; 2017 Dec; 6(12):2998-3013. PubMed ID: 29047224
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer.
Male H; Patel V; Jacob MA; Borrego-Diaz E; Wang K; Young DA; Wise AL; Huang C; Van Veldhuizen P; O'Brien-Ladner A; Williamson SK; Taylor SA; Tawfik O; Esfandyari T; Farassati F
Lung Cancer; 2012 Aug; 77(2):252-9. PubMed ID: 22498113
[TBL] [Abstract][Full Text] [Related]
3. RalA is overactivated in medulloblastoma.
Ginn KF; Fangman B; Terai K; Wise A; Ziazadeh D; Shah K; Gartrell R; Ricke B; Kimura K; Mathur S; Borrego-Diaz E; Farassati F
J Neurooncol; 2016 Oct; 130(1):99-110. PubMed ID: 27566179
[TBL] [Abstract][Full Text] [Related]
4. Ral overactivation in malignant peripheral nerve sheath tumors.
Bodempudi V; Yamoutpoor F; Pan W; Dudek AZ; Esfandyari T; Piedra M; Babovick-Vuksanovic D; Woo RA; Mautner VF; Kluwe L; Clapp DW; De Vries GH; Thomas SL; Kurtz A; Parada LF; Farassati F
Mol Cell Biol; 2009 Jul; 29(14):3964-74. PubMed ID: 19414599
[TBL] [Abstract][Full Text] [Related]
5. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.
Yan C; Theodorescu D
Pharmacol Rev; 2018 Jan; 70(1):1-11. PubMed ID: 29196555
[TBL] [Abstract][Full Text] [Related]
6. RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).
Ezzeldin M; Borrego-Diaz E; Taha M; Esfandyari T; Wise AL; Peng W; Rouyanian A; Asvadi Kermani A; Soleimani M; Patrad E; Lialyte K; Wang K; Williamson S; Abdulkarim B; Olyaee M; Farassati F
Mol Oncol; 2014 Jul; 8(5):1043-53. PubMed ID: 24785097
[TBL] [Abstract][Full Text] [Related]
7. Expression of ral GTPases, their effectors, and activators in human bladder cancer.
Smith SC; Oxford G; Baras AS; Owens C; Havaleshko D; Brautigan DL; Safo MK; Theodorescu D
Clin Cancer Res; 2007 Jul; 13(13):3803-13. PubMed ID: 17606711
[TBL] [Abstract][Full Text] [Related]
8. Ral GTPases in tumorigenesis: emerging from the shadows.
Kashatus DF
Exp Cell Res; 2013 Sep; 319(15):2337-42. PubMed ID: 23830877
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.
Smith SC; Baras AS; Owens CR; Dancik G; Theodorescu D
Cancer Res; 2012 Jul; 72(14):3480-91. PubMed ID: 22586063
[TBL] [Abstract][Full Text] [Related]
10. RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia.
Gu C; Feng M; Yin Z; Luo X; Yang J; Li Y; Li T; Wang R; Fei J
Oncotarget; 2016 Apr; 7(15):20561-73. PubMed ID: 26967392
[TBL] [Abstract][Full Text] [Related]
11. The RAL signaling network: Cancer and beyond.
Apken LH; Oeckinghaus A
Int Rev Cell Mol Biol; 2021; 361():21-105. PubMed ID: 34074494
[TBL] [Abstract][Full Text] [Related]
12. Ral GTPases: corrupting the exocyst in cancer cells.
Camonis JH; White MA
Trends Cell Biol; 2005 Jun; 15(6):327-32. PubMed ID: 15953551
[TBL] [Abstract][Full Text] [Related]
13. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.
Yin J; Pollock C; Tracy K; Chock M; Martin P; Oberst M; Kelly K
Mol Cell Biol; 2007 Nov; 27(21):7538-50. PubMed ID: 17709381
[TBL] [Abstract][Full Text] [Related]
14. Ral GTPases in Schwann cells promote radial axonal sorting in the peripheral nervous system.
Ommer A; Figlia G; Pereira JA; Datwyler AL; Gerber J; DeGeer J; Lalli G; Suter U
J Cell Biol; 2019 Jul; 218(7):2350-2369. PubMed ID: 31201267
[TBL] [Abstract][Full Text] [Related]
15. Activation of RalA is critical for Ras-induced tumorigenesis of human cells.
Lim KH; Baines AT; Fiordalisi JJ; Shipitsin M; Feig LA; Cox AD; Der CJ; Counter CM
Cancer Cell; 2005 Jun; 7(6):533-45. PubMed ID: 15950903
[TBL] [Abstract][Full Text] [Related]
16. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
17. Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer.
Győrffy B; Stelniec-Klotz I; Sigler C; Kasack K; Redmer T; Qian Y; Schäfer R
Oncotarget; 2015 May; 6(15):13334-46. PubMed ID: 26033452
[TBL] [Abstract][Full Text] [Related]
18. Ral GTPase Activation by Downregulation of RalGAP Enhances Oral Squamous Cell Carcinoma Progression.
Gao P; Liu S; Yoshida R; Shi CY; Yoshimachi S; Sakata N; Goto K; Kimura T; Shirakawa R; Nakayama H; Sakata J; Kawashiri S; Kato K; Wang XY; Horiuchi H
J Dent Res; 2019 Aug; 98(9):1011-1019. PubMed ID: 31329042
[TBL] [Abstract][Full Text] [Related]
19. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.
Lim KH; Brady DC; Kashatus DF; Ancrile BB; Der CJ; Cox AD; Counter CM
Mol Cell Biol; 2010 Jan; 30(2):508-23. PubMed ID: 19901077
[TBL] [Abstract][Full Text] [Related]
20. The RalGEF/Ral pathway: evaluating an intervention opportunity for Ras cancers.
Cooper JM; Bodemann BO; White MA
Enzymes; 2013; 34 Pt. B():137-56. PubMed ID: 25034103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
